Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Methods: Patients undergoing resection for mut BRAF CRLM were identified from prospectively maintained registries of the collaborating institutions. Overall survival (OS) and recurrence-free survival (RFS) were compared among patients with V600E versus non-V600E mutations, KRAS/BRAF comutation versus mut BRAF alone, microsatellite stability status (Microsatellite Stable (MSS) vs instable (MSI-high)), upfront resectable versus converted tumors, extrahepatic versus liver-limited disease, and intrahepatic recurrence treated with repeat hepatectomy versus nonoperative management.

Results: A total of 240 patients harboring BRAF -mutated tumors were included. BRAF V600E mutation was associated with shorter OS (30.6 vs 144 mo, P =0.004), but not RFS compared with non-V600E mutations. KRAS/BRAF comutation did not affect outcomes. MSS tumors were associated with shorter RFS (9.1 vs 26 mo, P <0.001) but not OS (33.5 vs 41 mo, P =0.3) compared with MSI-high tumors, whereas patients with resected converted disease had slightly worse RFS (8 vs 11 mo, P =0.01) and similar OS (30 vs 40 mo, P =0.4) compared with those with upfront resectable disease. Patients with extrahepatic disease had worse OS compared with those with liver-limited disease (8.8 vs 40 mo, P <0.001). Repeat hepatectomy after intrahepatic recurrence was associated with improved OS compared with nonoperative management (41 vs 18.7 mo, P =0.004). All results continued to hold true in the multivariable OS analysis.

Conclusions: Although surgery may be futile in patients with BRAF -mutated CRLM and concurrent extrahepatic disease, resection of converted disease resulted in encouraging survival in the absence of extrahepatic spread. Importantly, second hepatectomy in select patients with recurrence was associated with improved outcomes. Finally, MSI-high status identifies a better prognostic group, with regard to RFS while patients with non-V600E mutations have excellent prognosis.

Citing Articles

A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer.

Qi F, Gao N, Li J, Zhou C, Jiang J, Zhou B Mol Cancer. 2024; 23(1):239.

PMID: 39449040 PMC: 11515508. DOI: 10.1186/s12943-024-02155-z.

Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study.

Margonis G, Wang J, Boerner T, Moretto R, Buettner S, Andreatos N Br J Surg. 2024; 111(7.

PMID: 39051667 PMC: 11270119. DOI: 10.1093/bjs/znae176.

A critical appraisal of the current landscape of resectable BRAF mutated colorectal liver metastases: a systematic review.

Margonis G, Wang J, Papakonstantinou D, Beyer K, Kreis M, DAngelica M Chin Clin Oncol. 2024; 13(4):51.

PMID: 38859602 PMC: 11752564. DOI: 10.21037/cco-23-128.

Somatic Mutations in Surgically Treated Colorectal Liver Metastases: An Overview.

Wang J, Botvinov J, Bhatt A, Beyer K, Kreis M, Adam M Cells. 2024; 13(8.

PMID: 38667294 PMC: 11049420. DOI: 10.3390/cells13080679.

Adjuvant chemotherapy is associated with better oncological outcomes after ALPPS for colorectal liver metastases.

Alvarez F, Ardiles V, Chara C, de Santibanes M, Sanchez Claria R, Pekolj J Updates Surg. 2024; 76(3):855-868.

PMID: 38647857 DOI: 10.1007/s13304-024-01835-1.

References

Sahin I, Kazmi S, Yorio J, Bhadkamkar N, Kee B, Garrett C . Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. J Cancer. 2013; 4(4):320-2. PMC: 3619093. DOI: 10.7150/jca.3619. View

Wicherts D, de Haas R, Salloum C, Andreani P, Pascal G, Sotirov D . Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013; 100(6):808-18. DOI: 10.1002/bjs.9088. View

Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R . BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015; 26(10):2092-7. DOI: 10.1093/annonc/mdv290. View

Hernan M . Causal analyses of existing databases: no power calculations required. J Clin Epidemiol. 2021; 144:203-205. PMC: 8882204. DOI: 10.1016/j.jclinepi.2021.08.028. View

Steyerberg E, Vergouwe Y . Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014; 35(29):1925-31. PMC: 4155437. DOI: 10.1093/eurheartj/ehu207. View

Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu C . Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117(20):4623-32. PMC: 4257471. DOI: 10.1002/cncr.26086. View

Peduzzi P, Concato J, Feinstein A, Holford T . Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995; 48(12):1503-10. DOI: 10.1016/0895-4356(95)00048-8. View

Imai K, Adam R, Baba H . How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective. Ann Gastroenterol Surg. 2019; 3(5):476-486. PMC: 6749948. DOI: 10.1002/ags3.12276. View

Gagniere J, Dupre A, Gholami S, Pezet D, Boerner T, Gonen M . Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. Ann Surg. 2018; 271(1):147-154. DOI: 10.1097/SLA.0000000000002968. View

10.

Lam V, Spiro C, Laurence J, Johnston E, Hollands M, Pleass H . A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2011; 19(4):1292-301. DOI: 10.1245/s10434-011-2061-0. View

11.

Concato J, Peduzzi P, Holford T, Feinstein A . Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995; 48(12):1495-501. DOI: 10.1016/0895-4356(95)00510-2. View

12.

Karagkounis G, Torbenson M, Daniel H, Azad N, Diaz Jr L, Donehower R . Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013; 119(23):4137-44. PMC: 3967132. DOI: 10.1002/cncr.28347. View

13.

Olthof P, Huiskens J, Wicherts D, Huespe P, Ardiles V, Robles-Campos R . Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. Surgery. 2017; 161(4):909-919. DOI: 10.1016/j.surg.2016.10.032. View

14.

Sinicrope F, Shi Q, Smyrk T, Thibodeau S, Dienstmann R, Guinney J . Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2014; 148(1):88-99. PMC: 4274188. DOI: 10.1053/j.gastro.2014.09.041. View

15.

Bachet J, Moreno-Lopez N, Vigano L, Marchese U, Gelli M, Raoux L . BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. Br J Surg. 2019; 106(9):1237-1247. DOI: 10.1002/bjs.11180. View

16.

Jones J, Renfro L, Al-Shamsi H, Schrock A, Rankin A, Zhang B . BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35(23):2624-2630. PMC: 5549454. DOI: 10.1200/JCO.2016.71.4394. View

17.

Larki P, Gharib E, Taleghani M, Khorshidi F, Nazemalhosseini-Mojarad E, Aghdaei H . Coexistence of and Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. Cell J. 2017; 19(Suppl 1):113-117. PMC: 5448326. DOI: 10.22074/cellj.2017.5123. View

18.

Denbo J, Yamashita S, Passot G, Egger M, Chun Y, Kopetz S . RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg. 2016; 21(1):68-77. DOI: 10.1007/s11605-016-3189-9. View

19.

Simkens L, van Tinteren H, May A, Ten Tije A, Creemers G, Loosveld O . Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385(9980):1843-52. DOI: 10.1016/S0140-6736(14)62004-3. View

20.

Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M . Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2017; 16(3):e153-e163. DOI: 10.1016/j.clcc.2017.01.004. View